Biogen Appoints Amy Chevalier Efantis Vice President of Government Affairs
July 10 2017 - 7:30AM
Business Wire
Biogen (NASDAQ: BIIB) announced today the appointment of Amy
Chevalier Efantis as Vice President of Government Affairs,
effective July 17.
Ms. Efantis brings to Biogen more than two decades of
legislative, public policy, and advocacy experience in the
biopharma industry and the public sector. She will lead the
company’s federal and state government affairs activities from
Biogen’s Washington, D.C., office.
She joins Biogen from Boehringer Ingelheim Pharmaceuticals,
where she led the company’s Washington-based Government Affairs and
Public Policy team as Executive Director and Head of Office. Ms.
Efantis was also a Senior Director for the Pharmaceutical Research
and Manufacturers of America (PhRMA), working with member companies
on strategies related to legislation impacting the industry. Prior
to her move to biopharma, she served as Legislative Director to
former Alabama Congressman Artur Davis and as Senior Legislative
Assistant to former Wisconsin Congressman Tom Barrett.
“We are pleased to welcome Amy to Biogen and our mission to
innovate medicine in neuroscience,” said Susan Alexander, Executive
Vice President, Corporate Services. “Her experience will be
invaluable in our ongoing efforts to promote access to
life-changing therapies in multiple sclerosis, to implement newborn
screening for spinal muscular atrophy (SMA) and to raise awareness
of the importance of early detection of Alzheimer's disease.”
Ms. Efantis holds an undergraduate degree in history and
political science and a professional certification in secondary
education from the University of Wisconsin.
About BiogenThrough cutting-edge science and medicine,
Biogen discovers, develops and delivers worldwide innovative
therapies for people living with serious neurological and
neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in
biotechnology, and today the company has the leading portfolio of
medicines to treat multiple sclerosis; has introduced the first and
only approved treatment for spinal muscular atrophy; and is at the
forefront of neurology research for conditions including
Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral
sclerosis. Biogen also manufactures and commercializes biosimilars
of advanced biologics. For more information, please visit
www.biogen.com. Follow us on social media – Twitter, LinkedIn,
Facebook, YouTube.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170710005180/en/
BiogenMEDIA CONTACT:Matt Fearer, +1 781-464
3260public.affairs@biogen.comorINVESTOR CONTACT:Matt Calistri,
+1-781-464-2442IR@biogen.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024